Leif Hertz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leif Hertz has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Liang Peng
4 shared publicationsYe Chen
Henry M. Jackson FoundationBethesda, MD, United States
3 shared publicationsBaoman Li
2 shared publications- Ting Du
University of Rochester
2 shared publications Alexei Verkhratsky
1 shared publicationAng D. Sherpa
1 shared publication
Latest Publications
- Open Access
- 25 August 2017
- Published by Frontiers Media SA in Frontiers in Integrative Neuroscience
- Vol. 11, 18
Integration between Glycolysis and Glutamate-Glutamine Cycle Flux May Explain Preferential Glycolytic Increase during Brain Activation, Requiring Glutamate
The 1988 observation by Fox et al. that brief intense brain activation increases glycolysis (pyruvate formation from glucose) much more than oxidative metabolism has been abundantly confirmed. Specifically glycolytic increase was unexpected because the amount of ATP it generates is much smaller than that formed by subsequent oxidative metabolism of pyruvate. The present paper shows that preferential glycolysis can be explained by metabolic processes associated with activation of the glutamate-glutamine cycle. The flux in this cycle, which is essential for production of transmitter glutamate and GABA, equals 75% of brain glucose utilization and each turn is associated with utilization of ~1 glucose molecule. About one half of the association between cycle flux and glucose metabolism occurs during neuronal conversion of glutamine to glutamate in a process similar to the malate-aspartate shuttle (MAS) except that glutamate is supplied from glutamine, not formed from -ketoglutarate as during operation of conventional MAS. Regular MAS function is triggered by one oxidative process in the cytosol during glycolysis causing NAD+ reduction to NADH. Since NADH cannot cross the mitochondrial membrane for oxidation NAD+ is re-generated by conversion of cytosolic oxaloacetate (OAA) to malate, which enters the mitochondria for oxidation and in a cyclic process regenerates cytosolic OAA. Therefore MAS as well as the ‘pseudo-MAS’ necessary for neuronal glutamate formation can only operate together with cytosolic reduction of NAD+ to NADH. The major process causing NAD+ reduction is glycolysis which therefore also must occur during neuronal conversion of glutamine to glutamate and may energize vesicular glutamate uptake which preferentially uses glycolytically derived energy. Another major contributor to the association between glutamate-glutamine cycle and glucose utilization is the need for astrocytic pyruvate to generate glutamate. Although some oxidative metabolism occurs during glutamate formation it is only one half of that during normal tricarboxylic acid cycle function. Finally, glutamate’s receptor stimulation leads to large potassium ion (K+) release and subsequent transient astrocytic glycolysis preferring uptake followed by release and neuronal re-accumulation. The activation-induced preferential glycolysis diminishes with continued activation and is followed by an increased ratio between oxidative metabolism and glycolysis, reflecting oxidation of generated glutamate and accumulated
- 25 August 2017
- Published by Frontiers Media SA in Frontiers in Integrative Neuroscience
- Vol. 11, 18
Open AccessIntegration between Glycolysis and Glutamate-Glutamine Cycle Flux May Explain Preferential Glycolytic Increase during Brain Activation, Requiring Glutamate
The 1988 observation by Fox et al. that brief intense brain activation increases glycolysis (pyruvate formation from glucose) much more than oxidative metabolism has been abundantly confirmed. Specifically glycolytic increase was unexpected because the amount of ATP it generates is much smaller than that formed by subsequent oxidative metabolism of pyruvate. The present paper shows that preferential glycolysis can be explained by metabolic processes associated with activation of the glutamate-glutamine cycle. The flux in this cycle, which is essential for production of transmitter glutamate and GABA, equals 75% of brain glucose utilization and each turn is associated with utilization of ~1 glucose molecule. About one half of the association between cycle flux and glucose metabolism occurs during neuronal conversion of glutamine to glutamate in a process similar to the malate-aspartate shuttle (MAS) except that glutamate is supplied from glutamine, not formed from -ketoglutarate as during operation of conventional MAS. Regular MAS function is triggered by one oxidative process in the cytosol during glycolysis causing NAD+ reduction to NADH. Since NADH cannot cross the mitochondrial membrane for oxidation NAD+ is re-generated by conversion of cytosolic oxaloacetate (OAA) to malate, which enters the mitochondria for oxidation and in a cyclic process regenerates cytosolic OAA. Therefore MAS as well as the ‘pseudo-MAS’ necessary for neuronal glutamate formation can only operate together with cytosolic reduction of NAD+ to NADH. The major process causing NAD+ reduction is glycolysis which therefore also must occur during neuronal conversion of glutamine to glutamate and may energize vesicular glutamate uptake which preferentially uses glycolytically derived energy. Another major contributor to the association between glutamate-glutamine cycle and glucose utilization is the need for astrocytic pyruvate to generate glutamate. Although some oxidative metabolism occurs during glutamate formation it is only one half of that during normal tricarboxylic acid cycle function. Finally, glutamate’s receptor stimulation leads to large potassium ion (K+) release and subsequent transient astrocytic glycolysis preferring uptake followed by release and neuronal re-accumulation. The activation-induced preferential glycolysis diminishes with continued activation and is followed by an increased ratio between oxidative metabolism and glycolysis, reflecting oxidation of generated glutamate and accumulated
- 21 July 2017
- Published by Elsevier
List of Contributors
- Open Access
Glutamine-Glutamate Cycle Flux Is Similar in Cultured Astrocytes and Brain and Both Glutamate Production and Oxidation Are Mainly Catalyzed by Aspartate Aminotransferase
The glutamine-glutamate cycle provides neurons with astrocyte-generated glutamate/γ-aminobutyric acid (GABA) and oxidizes glutamate in astrocytes, and it returns released transmitter glutamate/GABA to neurons after astrocytic uptake. This review deals primarily with the glutamate/GABA generation/oxidation, although it also shows similarity between metabolic rates in cultured astrocytes and intact brain. A key point is identification of the enzyme(s) converting astrocytic α-ketoglutarate to glutamate and vice versa. Most experiments in cultured astrocytes, including those by one of us, suggest that glutamate formation is catalyzed by aspartate aminotransferase (AAT) and its degradation by glutamate dehydrogenase (GDH). Strongly supported by results shown in Table 1 we now propose that both reactions are primarily catalyzed by AAT. This is possible because the formation occurs in the cytosol and the degradation in mitochondria and they are temporally separate. High glutamate/glutamine concentrations abolish the need for glutamate production from α-ketoglutarate and due to metabolic coupling between glutamate synthesis and oxidation these high concentrations render AAT-mediated glutamate oxidation impossible. This necessitates the use of GDH under these conditions, shown by insensitivity of the oxidation to the transamination inhibitor aminooxyacetic acid (AOAA). Experiments using lower glutamate/glutamine concentration show inhibition of glutamate oxidation by AOAA, consistent with the coupled transamination reactions described here.
Open AccessGlutamine-Glutamate Cycle Flux Is Similar in Cultured Astrocytes and Brain and Both Glutamate Production and Oxidation Are Mainly Catalyzed by Aspartate Aminotransferase
The glutamine-glutamate cycle provides neurons with astrocyte-generated glutamate/γ-aminobutyric acid (GABA) and oxidizes glutamate in astrocytes, and it returns released transmitter glutamate/GABA to neurons after astrocytic uptake. This review deals primarily with the glutamate/GABA generation/oxidation, although it also shows similarity between metabolic rates in cultured astrocytes and intact brain. A key point is identification of the enzyme(s) converting astrocytic α-ketoglutarate to glutamate and vice versa. Most experiments in cultured astrocytes, including those by one of us, suggest that glutamate formation is catalyzed by aspartate aminotransferase (AAT) and its degradation by glutamate dehydrogenase (GDH). Strongly supported by results shown in Table 1 we now propose that both reactions are primarily catalyzed by AAT. This is possible because the formation occurs in the cytosol and the degradation in mitochondria and they are temporally separate. High glutamate/glutamine concentrations abolish the need for glutamate production from α-ketoglutarate and due to metabolic coupling between glutamate synthesis and oxidation these high concentrations render AAT-mediated glutamate oxidation impossible. This necessitates the use of GDH under these conditions, shown by insensitivity of the oxidation to the transamination inhibitor aminooxyacetic acid (AOAA). Experiments using lower glutamate/glutamine concentration show inhibition of glutamate oxidation by AOAA, consistent with the coupled transamination reactions described here.
- Open Access
- 8 January 2016
- Published by Frontiers Media SA in Frontiers in Integrative Neuroscience
- Vol. 9, 67
Sequential Astrocytic 5-HT2B Receptor Stimulation, [Ca2+]i Regulation, Glycogenolysis, Glutamate Synthesis, and K+ Homeostasis are Similar but Not Identical in Learning and Mood Regulation
Sequential Astrocytic 5-HT2B Receptor Stimulation, [Ca2+]i Regulation, Glycogenolysis, Glutamate Synthesis, and K+ Homeostasis are Similar but Not Identical in Learning and Mood Regulation
- 8 January 2016
- Published by Frontiers Media SA in Frontiers in Integrative Neuroscience
- Vol. 9, 67
Open AccessSequential Astrocytic 5-HT2B Receptor Stimulation, [Ca2+]i Regulation, Glycogenolysis, Glutamate Synthesis, and K+ Homeostasis are Similar but Not Identical in Learning and Mood Regulation
Sequential Astrocytic 5-HT2B Receptor Stimulation, [Ca2+]i Regulation, Glycogenolysis, Glutamate Synthesis, and K+ Homeostasis are Similar but Not Identical in Learning and Mood Regulation
- Open Access
- 13 November 2015
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 9, 308
Response: Commentary: Chronic SSRI Stimulation of Astrocytic 5-HT2B Receptors Change Multiple Gene Expressions/Editings and Metabolism of Glutamate, Glucose and Glycogen: A Potential Paradigm Shift
A Response to Commentary: Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift by Banas, S. M., Diaz, S. L., Doly, S., Belmer, A., and Maroteaux, L. (2015). Front. Behav. Neurosci. 9:207. doi: 10.3389/fnbeh.2015.00207 Hertz et al. (2015) provided data indicating that the indisputable SERT inhibition caused by SSRIs is an epiphenomenon. Instead we pointed toward acute and chronic effects of fluoxetine on 5-HT2B receptor stimulation in astrocytes (in culture or freshly isolated from brains of mice treated with fluoxetine for 14 days). Stimulation by fluoxetine of the astrocytic 5-HT2B receptor causes a multitude of effects that in astrocyte cultures could be prevented by drug- or siRNA-induced 5-HT2B receptor inhibition (Figure 1). This stimulation activates complex signaling pathways, including EGF receptor transactivation, a signal pathway in which a G-protein-coupled receptor (GPCR) signal leads to release of a growth factor, which activates the EGF receptor-tyrosinekinase in the same or adjacent cells. Astrocytes express a number of GPCRs and play key roles in brain function (Hansson and Rönnbäck, 2004; Fields, 2009). The autocrine effects of growth factor release may regulate gene expression and alter cell functions in the astrocytes themselves and the paracrine effects provide opportunities for effects on their neuronal neighbors. Our studies in mice treated with fluoxetine for 2 weeks showed multiple gene upregulations and editings (Li et al., 2012; Hertz et al., 2015), which altered the function of the gene product in kainate receptors, 5-HT2 receptors, phospholipase cPLA2, a Ca2+ L-channel gene and nucleoside transporter genes. These changes occurred mainly in astrocytes but some were neuronal. They occurred together with effects on metabolism of glucose and glycogen and turnover of glutamate and GABA, consistent with evidence of increased glutamatergic activity and decreased GABA-ergic activity in patients suffering from major depression, which are reverted by successful therapy; similarly, glucose metabolism is decreased in depressed patients and increases following treatment (Hertz et al., 2015). Figure 1. Phosphorylation of ERK1∕2, a known target of 5-HT2B receptor stimulation in astrocytes. After treatment with phosphate-buffered saline, PBS (Control), transfection solution without siRNA (siRNA (−)) or siRNA specific to 5-HT2B receptor [siRNA (+)], culturing of well differentiated astrocytes (at least 3 weeks in culture and treated with dibutyryl cAMP [dBcAMP]), was continued for another week. Since 5-HT2B receptor expression in the cultures had been normal until the exposure to siRNA the result indicates an effect on mature astrocytes. This contrasts the non-conditional gene knockouts of intact mice used by Diaz et al. (2012), where effects during development cannot be ruled out. For the phosphorylation experiments, the cells were incubated for 20 min in serum-free medium in the absence of any drug (Control) or in the presence of 10 μM fluoxetine. (1) Immunoblot showing gene expression of phosphorylated and non-phosphorylated ERK 1 and 2 (p-ERK1 and ERK1 and p-ERK2 and ERK2) from representative experiments. Similar results were obtained in three independent experiments. Average ERK phosphorylation was quantitated as ratios between p-ERK1 and ERK1 (2) and between p-ERK2 and ERK2 (3). SEM values are indicated by vertical bars. * Indicates statistically significant (P < 0.05) difference from all other groups for ERK1 and ERK2. (From Li et al., 2008). A commentary by Banas et al. (2015) claim that we forgot important information provided by Diaz et al. (2012), including absence of antidepressant effects of fluoxetine or the 5-HT2B agonist BW723C86 in mice lacking the serotonin transporter (SERT) or differentiated serotonergic neurons. They allege that these data rule out that the antidepressant effects of fluoxetine or BW723C86 could be SERT-independent (as claimed by us) and show that serotonergic neurons expressing SERT are necessary for the 5-HT2B receptor effects exerted by fluoxetine (and other 5-HT2B receptor agonists). They further remind us that Launay et al. (2006) in neuronal cultures from raphe nuclei demonstrated 5-HT2B receptor-mediated control of SERT activity via 5-HT2B receptor-promoted SERT phosphorylations. This should explain the finding by Diaz et al. (2012) that there are no antidepressant effects of either fluoxetine or BW723C86 in mice knocked-out for SERT or lacking differentiated serotonin neurons. These data should also rule out that the antidepressant effects of 5-HT2B agonists, including fluoxetine, could be independent of SERT and explain the conclusion by the Maroteaux group (Diaz et al., 2012) that fluoxetine acts by 5-HT2B receptor-mediated regulation of SERT in a cell autonomous manner. We were well aware of the lack of antidepressant effect in SERT knock-outs described by Diaz et al. (2012) and of their reference to the paper by Launay et al. (2006), but did not comment on these points, because they are irrelevant. The lack of effect in the knock-outs does not prove any dependence on SERT, because Qu et al. (2005) showed that the direct DOI-mediated stimulation of 5-HT2 receptor activation of phospholipase A2 (cPLA2) and subsequent arachidonic acid release and metabolism seen in normal mice is abolished in mice lacking SERT. There is no information in the literature that DOI should interact with SERT. Although Qu et al. indicated DOI as a 5-HT2A∕C agonist it also activates the 5-HT2B receptor (Pineda-Farias et al., 2015). Stimulation of this receptor is the most likely reason for the response in wild-type animals, because fluoxetine acutely stimulates astrocytic 5-HT2B receptors in cultured astrocytes (Li et al., 2008; Qiao et al., 2015) and after chronic administration (14 days) to mice upregulates this receptor in astrocytes but not in neurons (Li et al., 2012; Hertz et al., 2015). Moreover, cPLA2-mediated signal transduction is increased by acute fluoxetine administration in unanesthetized rats (Qu et al., 2003) and phospholipase A2 activity is potently stimulated by the SSRI sertraline in yeast (Rainey et al., 2010). Since direct stimulation with an agonist has no effect in these animals, the lack of fluoxetine effect in the knockouts does not prove fluoxetine dependence on SERT in adult brain. With respect to the paper by Launay et al. it 2006 deals with extremely young cells. It does therefore not show that fluoxetine stimulates the 5-HT2B receptor in mature individuals, because Homberg et al. (2011) and Sarkar et al. (2014) have shown that the serotonergic system in the immature brain functions in a completely different manner than in the mature brain. Banas et al. also claim we changed results. However, the figure in Hertz et al. (2012) and in Kong et al. (2002) is—of course—the same and any reader has the opportunity to calculate Ki values based on the graph and the concentrations of mesulergine. The Zhang et al. (2010) paper, referred to in the Banas commentary clearly indicates the difference between SSRI affinity during acute and chronic treatment. There is no major difference between the acute affinity found by ourselves and others, and we are the only authors who have measured affinities for SSRIs in chronically treated cells. The suggestion that effects on muscarinic acetylcholine and histamine receptors or other monoamine transporters should explain our observations independently of “putative” direct agonist effects at 5-HT2B receptors is invalidated by the observation by Li et al. (2008) that “ERK phosphorylation was abolished by SB204741, a universal 5-HT2 receptor antagonist, and in 5-HT2B receptor-depleted cells (see Figure 1), but unaffected by 5-HT2A or 5-HT2C receptor antagonists.” Fluoxetine stimulation of astrocytic 5-HT2B receptors was confirmed by Qiao et al. (2015). The “putative” receptors were demonstrated on both well-differentiated astrocyte cultures and freshly isolated astrocytes (Li et al., 2008, 2012; Peng et al., 2010; Zhang et al., 2010). The commentary by Banas et al. has accordingly not altered our original conclusions but rather strengthened it. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Banas, S. M., Diaz, S. L., Doly, S., Belmer, A., and Maroteaux, L. (2015). Commentary: chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front. Behav. Neurosci. 9:207. doi: 10.3389/fnbeh.2015.00207 PubMed Abstract | CrossRef Full Text | Google Scholar Diaz, S. L., Doly, S., Narboux-Nême, N., Fernández, S., Mazot, P., Banas, S. M., et al. (2012). 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol. Psychiatry 17, 154–163. doi: 10.1038/mp.2011.159 PubMed Abstract | CrossRef Full Text | Google Scholar Fields, R. D. (2009). The Other Brain: From Dementia to Schizophrenia, How New Discoveries about the Brain Are Revolutionizing Medicine and Science. New York, NY: Simon and Schuster. Google Scholar Hansson, E., and Rönnbäck, L. (2004). “Astrocytic receptors and second messenger systems,” in Non-neuronal Cells of the Nervous System: Function and Dysfunction II, ed L. Hertz (Amsterdam: Elsevier), 475–501. Hertz, L., Li, B., Song, D., Ren, J., Dong, L., Chen, Y., et al. (2012). Astrocytes as a 5-HT2B-mediated SERT-independent SSRI target, slowly altering depression-associated genes and function. Curr. Signal Transduct. Ther. 7, 65–80. doi: 10.2174/1574362799278154 CrossRef Full Text | Google Scholar Hertz, L., Rothman, D. L., Li, B., and Peng, L. (2015). Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front. Behav. Neurosci. 9:25. doi: 10.3389/fnbeh.2015.00025 PubMed Abstract | CrossRef Full Text | Google Scholar Homberg, J. R., Olivier, J. D., Blom, T., Arentsen, T., van Brunschot, C., Schipper, P., et al. (2011). Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS ONE 6:e16646. doi: 10.1371/journal.pone.0016646 PubMed Abstract | CrossRef Full Text | Google Scholar Kong, E. K., Peng, L., Chen, Y., Yu, A. C., and Hertz, L. (2002). Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem. Res. 27, 113–120. doi: 10.1023/A:1014862808126 PubMed Abstract | CrossRef Full Text | Google Scholar Launay, J. M., Schneider, B., Loric, S., Da Prada, M., and Kellermann, O. (2006). Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J. 20, 1843–1854. doi: 10.1096/fj.06-5724com PubMed Abstract | CrossRef Full Text | Google Scholar Li, B., Dong, L., Wang, B., Cai, L., Jiang, N., and Peng, L. (2012). Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia. Neurochem. Res. 37, 2480–2495. doi: 10.1007/s11064-012-0814-1 PubMed Abstract | CrossRef Full Text | Google Scholar Li, B., Zhang, S., Zhang, H., Nu, W., Cai, L., Hertz, L., et al. (2008). Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacol. (Berl.) 201, 443–458. doi: 10.1007/s00213-008-1306-5 PubMed Abstract | CrossRef Full Text | Google Scholar Peng, L., Li, B., Du, T., Kong, E. K., Hu, X., Zhang, S., et al. (2010). Astrocytic transactivation by alpha2A-adrenergic and 5-HT2B serotonergic signaling. Neurochem. Int. 57, 421–431. doi: 10.1016/j.neuint.2010.04.018 PubMed Abstract | CrossRef Full Text | Google Scholar Pineda-Farias, J. B., Velázquez-Lagunas, I., Barragán-Iglesias, P., Cervantes-Durán, C., and Granados-Soto, V. (2015). 5-HT2B receptor antagonists reduce nerve injury-induced tactile allodynia and expression of 5-HT2B receptors. Drug Dev. Res. 76, 31–39. doi: 10.1002/ddr.21238 PubMed Abstract | CrossRef Full Text | Google Scholar Qiao, J., Wang, J., Wang, H., Zhang, Y., Zhu, S., Adilijiang, A., et al. (2015). Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model. Glia. doi: 10.1002/glia.22926. [Epub ahead of print]. PubMed Abstract | CrossRef Full Text | Google Scholar Qu, Y., Chang, L., Klaff, J., Seemann, R., and Rapoport, S. I. (2003). Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology 28, 1219–1226. doi: 10.1038/sj.npp.1300177 PubMed Abstract | CrossRef Full Text | Google Scholar Qu, Y., Villacreses, N., Murphy, D. L., and Rapoport, S. I. (2005). 5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacol. (Berl.) 180, 12–20. doi: 10.1007/s00213-005-2231-5 PubMed Abstract | CrossRef Full Text | Google Scholar Rainey, M. M., Korostyshevsky, D., Lee, S., and Perlstein, E. O. (2010). The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast. Genetics 185, 1221–1233. doi: 10.1534/genetics.110.117846 PubMed Abstract | CrossRef Full Text | Google Scholar Sarkar, A., Chachra, P., and Vaidya, V. A. (2014). Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation. Biol. Psychiatry 76, 858–868. doi: 10.1016/j.biopsych.2013.11.005 PubMed Abstract | CrossRef Full Text | Google Scholar Zhang, S., Li, B., Lovatt, D., Xu, J., Song, D., Goldman, S. A., et al. (2010). 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional ‘serotonin-specific reuptake inhibitors’. Neuron Glia. Biol. 6, 113–125. doi: 10.1017/S1740925X10000141 PubMed Abstract | CrossRef Full Text | Google Scholar Keywords: 5-HT2B receptor, serotonin transporter, SSRIs, astrocytic transactivation, PLA2 Citation: Hertz L, Rothman DL, Li B and Peng L (2015) Response: Commentary: Chronic SSRI Stimulation of Astrocytic 5-HT2B Receptors Change Multiple Gene Expressions/Editings and Metabolism of Glutamate, Glucose and Glycogen: A Potential Paradigm Shift. Front. Behav. Neurosci. 9:308. doi: 10.3389/fnbeh.2015.00308 Received: 14 September 2015; Accepted: 30 October 2015; Published: 13 November 2015. Edited by: Reviewed by: Copyright © 2015 Hertz, Rothman, Li and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Leif Hertz, lhertz538@gmail.com
- 13 November 2015
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 9, 308
Open AccessResponse: Commentary: Chronic SSRI Stimulation of Astrocytic 5-HT2B Receptors Change Multiple Gene Expressions/Editings and Metabolism of Glutamate, Glucose and Glycogen: A Potential Paradigm Shift
A Response to Commentary: Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift by Banas, S. M., Diaz, S. L., Doly, S., Belmer, A., and Maroteaux, L. (2015). Front. Behav. Neurosci. 9:207. doi: 10.3389/fnbeh.2015.00207 Hertz et al. (2015) provided data indicating that the indisputable SERT inhibition caused by SSRIs is an epiphenomenon. Instead we pointed toward acute and chronic effects of fluoxetine on 5-HT2B receptor stimulation in astrocytes (in culture or freshly isolated from brains of mice treated with fluoxetine for 14 days). Stimulation by fluoxetine of the astrocytic 5-HT2B receptor causes a multitude of effects that in astrocyte cultures could be prevented by drug- or siRNA-induced 5-HT2B receptor inhibition (Figure 1). This stimulation activates complex signaling pathways, including EGF receptor transactivation, a signal pathway in which a G-protein-coupled receptor (GPCR) signal leads to release of a growth factor, which activates the EGF receptor-tyrosinekinase in the same or adjacent cells. Astrocytes express a number of GPCRs and play key roles in brain function (Hansson and Rönnbäck, 2004; Fields, 2009). The autocrine effects of growth factor release may regulate gene expression and alter cell functions in the astrocytes themselves and the paracrine effects provide opportunities for effects on their neuronal neighbors. Our studies in mice treated with fluoxetine for 2 weeks showed multiple gene upregulations and editings (Li et al., 2012; Hertz et al., 2015), which altered the function of the gene product in kainate receptors, 5-HT2 receptors, phospholipase cPLA2, a Ca2+ L-channel gene and nucleoside transporter genes. These changes occurred mainly in astrocytes but some were neuronal. They occurred together with effects on metabolism of glucose and glycogen and turnover of glutamate and GABA, consistent with evidence of increased glutamatergic activity and decreased GABA-ergic activity in patients suffering from major depression, which are reverted by successful therapy; similarly, glucose metabolism is decreased in depressed patients and increases following treatment (Hertz et al., 2015). Figure 1. Phosphorylation of ERK1∕2, a known target of 5-HT2B receptor stimulation in astrocytes. After treatment with phosphate-buffered saline, PBS (Control), transfection solution without siRNA (siRNA (−)) or siRNA specific to 5-HT2B receptor [siRNA (+)], culturing of well differentiated astrocytes (at least 3 weeks in culture and treated with dibutyryl cAMP [dBcAMP]), was continued for another week. Since 5-HT2B receptor expression in the cultures had been normal until the exposure to siRNA the result indicates an effect on mature astrocytes. This contrasts the non-conditional gene knockouts of intact mice used by Diaz et al. (2012), where effects during development cannot be ruled out. For the phosphorylation experiments, the cells were incubated for 20 min in serum-free medium in the absence of any drug (Control) or in the presence of 10 μM fluoxetine. (1) Immunoblot showing gene expression of phosphorylated and non-phosphorylated ERK 1 and 2 (p-ERK1 and ERK1 and p-ERK2 and ERK2) from representative experiments. Similar results were obtained in three independent experiments. Average ERK phosphorylation was quantitated as ratios between p-ERK1 and ERK1 (2) and between p-ERK2 and ERK2 (3). SEM values are indicated by vertical bars. * Indicates statistically significant (P < 0.05) difference from all other groups for ERK1 and ERK2. (From Li et al., 2008). A commentary by Banas et al. (2015) claim that we forgot important information provided by Diaz et al. (2012), including absence of antidepressant effects of fluoxetine or the 5-HT2B agonist BW723C86 in mice lacking the serotonin transporter (SERT) or differentiated serotonergic neurons. They allege that these data rule out that the antidepressant effects of fluoxetine or BW723C86 could be SERT-independent (as claimed by us) and show that serotonergic neurons expressing SERT are necessary for the 5-HT2B receptor effects exerted by fluoxetine (and other 5-HT2B receptor agonists). They further remind us that Launay et al. (2006) in neuronal cultures from raphe nuclei demonstrated 5-HT2B receptor-mediated control of SERT activity via 5-HT2B receptor-promoted SERT phosphorylations. This should explain the finding by Diaz et al. (2012) that there are no antidepressant effects of either fluoxetine or BW723C86 in mice knocked-out for SERT or lacking differentiated serotonin neurons. These data should also rule out that the antidepressant effects of 5-HT2B agonists, including fluoxetine, could be independent of SERT and explain the conclusion by the Maroteaux group (Diaz et al., 2012) that fluoxetine acts by 5-HT2B receptor-mediated regulation of SERT in a cell autonomous manner. We were well aware of the lack of antidepressant effect in SERT knock-outs described by Diaz et al. (2012) and of their reference to the paper by Launay et al. (2006), but did not comment on these points, because they are irrelevant. The lack of effect in the knock-outs does not prove any dependence on SERT, because Qu et al. (2005) showed that the direct DOI-mediated stimulation of 5-HT2 receptor activation of phospholipase A2 (cPLA2) and subsequent arachidonic acid release and metabolism seen in normal mice is abolished in mice lacking SERT. There is no information in the literature that DOI should interact with SERT. Although Qu et al. indicated DOI as a 5-HT2A∕C agonist it also activates the 5-HT2B receptor (Pineda-Farias et al., 2015). Stimulation of this receptor is the most likely reason for the response in wild-type animals, because fluoxetine acutely stimulates astrocytic 5-HT2B receptors in cultured astrocytes (Li et al., 2008; Qiao et al., 2015) and after chronic administration (14 days) to mice upregulates this receptor in astrocytes but not in neurons (Li et al., 2012; Hertz et al., 2015). Moreover, cPLA2-mediated signal transduction is increased by acute fluoxetine administration in unanesthetized rats (Qu et al., 2003) and phospholipase A2 activity is potently stimulated by the SSRI sertraline in yeast (Rainey et al., 2010). Since direct stimulation with an agonist has no effect in these animals, the lack of fluoxetine effect in the knockouts does not prove fluoxetine dependence on SERT in adult brain. With respect to the paper by Launay et al. it 2006 deals with extremely young cells. It does therefore not show that fluoxetine stimulates the 5-HT2B receptor in mature individuals, because Homberg et al. (2011) and Sarkar et al. (2014) have shown that the serotonergic system in the immature brain functions in a completely different manner than in the mature brain. Banas et al. also claim we changed results. However, the figure in Hertz et al. (2012) and in Kong et al. (2002) is—of course—the same and any reader has the opportunity to calculate Ki values based on the graph and the concentrations of mesulergine. The Zhang et al. (2010) paper, referred to in the Banas commentary clearly indicates the difference between SSRI affinity during acute and chronic treatment. There is no major difference between the acute affinity found by ourselves and others, and we are the only authors who have measured affinities for SSRIs in chronically treated cells. The suggestion that effects on muscarinic acetylcholine and histamine receptors or other monoamine transporters should explain our observations independently of “putative” direct agonist effects at 5-HT2B receptors is invalidated by the observation by Li et al. (2008) that “ERK phosphorylation was abolished by SB204741, a universal 5-HT2 receptor antagonist, and in 5-HT2B receptor-depleted cells (see Figure 1), but unaffected by 5-HT2A or 5-HT2C receptor antagonists.” Fluoxetine stimulation of astrocytic 5-HT2B receptors was confirmed by Qiao et al. (2015). The “putative” receptors were demonstrated on both well-differentiated astrocyte cultures and freshly isolated astrocytes (Li et al., 2008, 2012; Peng et al., 2010; Zhang et al., 2010). The commentary by Banas et al. has accordingly not altered our original conclusions but rather strengthened it. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Banas, S. M., Diaz, S. L., Doly, S., Belmer, A., and Maroteaux, L. (2015). Commentary: chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front. Behav. Neurosci. 9:207. doi: 10.3389/fnbeh.2015.00207 PubMed Abstract | CrossRef Full Text | Google Scholar Diaz, S. L., Doly, S., Narboux-Nême, N., Fernández, S., Mazot, P., Banas, S. M., et al. (2012). 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol. Psychiatry 17, 154–163. doi: 10.1038/mp.2011.159 PubMed Abstract | CrossRef Full Text | Google Scholar Fields, R. D. (2009). The Other Brain: From Dementia to Schizophrenia, How New Discoveries about the Brain Are Revolutionizing Medicine and Science. New York, NY: Simon and Schuster. Google Scholar Hansson, E., and Rönnbäck, L. (2004). “Astrocytic receptors and second messenger systems,” in Non-neuronal Cells of the Nervous System: Function and Dysfunction II, ed L. Hertz (Amsterdam: Elsevier), 475–501. Hertz, L., Li, B., Song, D., Ren, J., Dong, L., Chen, Y., et al. (2012). Astrocytes as a 5-HT2B-mediated SERT-independent SSRI target, slowly altering depression-associated genes and function. Curr. Signal Transduct. Ther. 7, 65–80. doi: 10.2174/1574362799278154 CrossRef Full Text | Google Scholar Hertz, L., Rothman, D. L., Li, B., and Peng, L. (2015). Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front. Behav. Neurosci. 9:25. doi: 10.3389/fnbeh.2015.00025 PubMed Abstract | CrossRef Full Text | Google Scholar Homberg, J. R., Olivier, J. D., Blom, T., Arentsen, T., van Brunschot, C., Schipper, P., et al. (2011). Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS ONE 6:e16646. doi: 10.1371/journal.pone.0016646 PubMed Abstract | CrossRef Full Text | Google Scholar Kong, E. K., Peng, L., Chen, Y., Yu, A. C., and Hertz, L. (2002). Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem. Res. 27, 113–120. doi: 10.1023/A:1014862808126 PubMed Abstract | CrossRef Full Text | Google Scholar Launay, J. M., Schneider, B., Loric, S., Da Prada, M., and Kellermann, O. (2006). Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J. 20, 1843–1854. doi: 10.1096/fj.06-5724com PubMed Abstract | CrossRef Full Text | Google Scholar Li, B., Dong, L., Wang, B., Cai, L., Jiang, N., and Peng, L. (2012). Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia. Neurochem. Res. 37, 2480–2495. doi: 10.1007/s11064-012-0814-1 PubMed Abstract | CrossRef Full Text | Google Scholar Li, B., Zhang, S., Zhang, H., Nu, W., Cai, L., Hertz, L., et al. (2008). Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacol. (Berl.) 201, 443–458. doi: 10.1007/s00213-008-1306-5 PubMed Abstract | CrossRef Full Text | Google Scholar Peng, L., Li, B., Du, T., Kong, E. K., Hu, X., Zhang, S., et al. (2010). Astrocytic transactivation by alpha2A-adrenergic and 5-HT2B serotonergic signaling. Neurochem. Int. 57, 421–431. doi: 10.1016/j.neuint.2010.04.018 PubMed Abstract | CrossRef Full Text | Google Scholar Pineda-Farias, J. B., Velázquez-Lagunas, I., Barragán-Iglesias, P., Cervantes-Durán, C., and Granados-Soto, V. (2015). 5-HT2B receptor antagonists reduce nerve injury-induced tactile allodynia and expression of 5-HT2B receptors. Drug Dev. Res. 76, 31–39. doi: 10.1002/ddr.21238 PubMed Abstract | CrossRef Full Text | Google Scholar Qiao, J., Wang, J., Wang, H., Zhang, Y., Zhu, S., Adilijiang, A., et al. (2015). Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model. Glia. doi: 10.1002/glia.22926. [Epub ahead of print]. PubMed Abstract | CrossRef Full Text | Google Scholar Qu, Y., Chang, L., Klaff, J., Seemann, R., and Rapoport, S. I. (2003). Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology 28, 1219–1226. doi: 10.1038/sj.npp.1300177 PubMed Abstract | CrossRef Full Text | Google Scholar Qu, Y., Villacreses, N., Murphy, D. L., and Rapoport, S. I. (2005). 5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacol. (Berl.) 180, 12–20. doi: 10.1007/s00213-005-2231-5 PubMed Abstract | CrossRef Full Text | Google Scholar Rainey, M. M., Korostyshevsky, D., Lee, S., and Perlstein, E. O. (2010). The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast. Genetics 185, 1221–1233. doi: 10.1534/genetics.110.117846 PubMed Abstract | CrossRef Full Text | Google Scholar Sarkar, A., Chachra, P., and Vaidya, V. A. (2014). Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation. Biol. Psychiatry 76, 858–868. doi: 10.1016/j.biopsych.2013.11.005 PubMed Abstract | CrossRef Full Text | Google Scholar Zhang, S., Li, B., Lovatt, D., Xu, J., Song, D., Goldman, S. A., et al. (2010). 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional ‘serotonin-specific reuptake inhibitors’. Neuron Glia. Biol. 6, 113–125. doi: 10.1017/S1740925X10000141 PubMed Abstract | CrossRef Full Text | Google Scholar Keywords: 5-HT2B receptor, serotonin transporter, SSRIs, astrocytic transactivation, PLA2 Citation: Hertz L, Rothman DL, Li B and Peng L (2015) Response: Commentary: Chronic SSRI Stimulation of Astrocytic 5-HT2B Receptors Change Multiple Gene Expressions/Editings and Metabolism of Glutamate, Glucose and Glycogen: A Potential Paradigm Shift. Front. Behav. Neurosci. 9:308. doi: 10.3389/fnbeh.2015.00308 Received: 14 September 2015; Accepted: 30 October 2015; Published: 13 November 2015. Edited by: Reviewed by: Copyright © 2015 Hertz, Rothman, Li and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Leif Hertz, lhertz538@gmail.com
- 21 July 2014
- Published by Springer Nature
- Vol. 11, 31-54
Glycogenolysis and Purinergic Signaling
Both ATP and glutamate are on one hand essential metabolites in brain and on the other serve a signaling function as transmitters. However, there is the major difference that the flux in the pathway producing transmitter glutamate is comparable to the rate of glucose metabolism in brain, whereas that producing transmitter ATP is orders of magnitude smaller than the metabolic turnover between ATP and ADP. Moreover, de novo glutamate production occurs exclusively in astrocytes, whereas transmitter ATP is produced both in neurons and astrocytes. This chapter deals only with ATP and exclusively with its formation and release in astrocytes, and it focuses on potential associations with glycogenolysis, which is known to be indispensable for the synthesis of glutamate. Glycogenolysis is dependent upon an increase in free intracellular Ca2+ concentration (Ca2+]i). It can be further stimulated by cAMP, but in contrast to widespread beliefs, cAMP can on its own not induce glycogenolysis. Astrocytes generate ATP from accumulated adenosine, and this process does not seem to require glycogenolysis. A minor amount of the generated ATP is utilized as a transmitter, and its synthesis requires the presence of the mainly intracellular nucleoside transporter ENT3. Many transmitters as well as extracellular K+ concentrations high enough to open the voltage-sensitive L-channels for Ca2+ cause a release of transmitter ATP from astrocytes. Adenosine and ATP induce release of ATP by action at several different purinergic receptors. The release evoked by transmitters or elevated K+ concentrations is abolished by DAB, an inhibitor of glycogenolysis.
- 21 July 2014
- Published by Springer Nature
- Vol. 11, 31-54
Glycogenolysis and Purinergic Signaling
Both ATP and glutamate are on one hand essential metabolites in brain and on the other serve a signaling function as transmitters. However, there is the major difference that the flux in the pathway producing transmitter glutamate is comparable to the rate of glucose metabolism in brain, whereas that producing transmitter ATP is orders of magnitude smaller than the metabolic turnover between ATP and ADP. Moreover, de novo glutamate production occurs exclusively in astrocytes, whereas transmitter ATP is produced both in neurons and astrocytes. This chapter deals only with ATP and exclusively with its formation and release in astrocytes, and it focuses on potential associations with glycogenolysis, which is known to be indispensable for the synthesis of glutamate. Glycogenolysis is dependent upon an increase in free intracellular Ca2+ concentration (Ca2+]i). It can be further stimulated by cAMP, but in contrast to widespread beliefs, cAMP can on its own not induce glycogenolysis. Astrocytes generate ATP from accumulated adenosine, and this process does not seem to require glycogenolysis. A minor amount of the generated ATP is utilized as a transmitter, and its synthesis requires the presence of the mainly intracellular nucleoside transporter ENT3. Many transmitters as well as extracellular K+ concentrations high enough to open the voltage-sensitive L-channels for Ca2+ cause a release of transmitter ATP from astrocytes. Adenosine and ATP induce release of ATP by action at several different purinergic receptors. The release evoked by transmitters or elevated K+ concentrations is abolished by DAB, an inhibitor of glycogenolysis.
- Open Access
- 1 April 2014
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 5, 54
Serotonin mediation of early memory formation via 5-HT2B receptor-induced glycogenolysis in the day-old chick
Investigation of the effects of serotonin on memory formation in the chick revealed an action on at least two 5HT receptors. Serotonin injected intracerebrally produced a biphasic effect on memory consolidation with enhancement at low doses and inhibition at higher doses. The non-selective 5HT receptor antagonist methiothepin and the selective 5HT2B/C receptor antagonist SB221284 both inhibited memory, suggesting actions of serotonin on at least 2 different receptor subtypes. The 5HT2B/C and astrocyte-specific 5-HT receptor agonists, fluoxetine and paroxetine, enhanced memory and the effect was attributed to glycogenolysis. Inhibition of glycogenolysis with a low dose of DAB prevented both serotonin and fluoxetine from enhancing memory during short-term memory but not during intermediate memory. The role of serotonin on the 5HT2B/C receptor appears to involve glycogen breakdown in astrocytes during short-term memory, whereas other published evidence attributes the second period of glycogenolysis to noradrenaline.
- 1 April 2014
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 5, 54
Open AccessSerotonin mediation of early memory formation via 5-HT2B receptor-induced glycogenolysis in the day-old chick
Investigation of the effects of serotonin on memory formation in the chick revealed an action on at least two 5HT receptors. Serotonin injected intracerebrally produced a biphasic effect on memory consolidation with enhancement at low doses and inhibition at higher doses. The non-selective 5HT receptor antagonist methiothepin and the selective 5HT2B/C receptor antagonist SB221284 both inhibited memory, suggesting actions of serotonin on at least 2 different receptor subtypes. The 5HT2B/C and astrocyte-specific 5-HT receptor agonists, fluoxetine and paroxetine, enhanced memory and the effect was attributed to glycogenolysis. Inhibition of glycogenolysis with a low dose of DAB prevented both serotonin and fluoxetine from enhancing memory during short-term memory but not during intermediate memory. The role of serotonin on the 5HT2B/C receptor appears to involve glycogen breakdown in astrocytes during short-term memory, whereas other published evidence attributes the second period of glycogenolysis to noradrenaline.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Integrative Neuroscience
- Vol. 7, 20
Brain glycogenolysis, adrenoceptors, pyruvate carboxylase, Na+,K+-ATPase and Marie E. Gibbs' pioneering learning studies
The involvement of glycogenolysis, occurring in astrocytes but not in neurons, in learning is undisputed (Duran et al., JCBFM, in press). According to one school of thought the role of astrocytes for learning is restricted to supply of substrate for neuronal oxidative metabolism. The present ‘perspective’ suggests a more comprehensive and complex role, made possible by lack of glycogen degradation, unless specifically induced by either i) activation of astrocytic receptors, perhaps especially beta-adrenergic, or ii) even small increases in extracellular K+ concentration above its normal resting level. It discusses i) the known importance of glycogenolysis for glutamate formation, requiring pyruvate carboxylation; ii) the established role of K+-stimulated glycogenolysis for K+ uptake in cultured astrocytes, which probably indicates that astrocytes are an integral part of cellular K+ homeostasis in the brain in vivo; and iii) the plausible role of transmitter-induced glycogenolysis, stimulating Na+,K+-ATPase/NKCC1 activity and thereby contributing both to the post-excitatory undershoot in extracellular K+ concentration and the memory-enhancing effect of transmitter-mediated reduction of slow neuronal afterhyperpolarization (sAHP).
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Integrative Neuroscience
- Vol. 7, 20
Open AccessBrain glycogenolysis, adrenoceptors, pyruvate carboxylase, Na+,K+-ATPase and Marie E. Gibbs' pioneering learning studies
The involvement of glycogenolysis, occurring in astrocytes but not in neurons, in learning is undisputed (Duran et al., JCBFM, in press). According to one school of thought the role of astrocytes for learning is restricted to supply of substrate for neuronal oxidative metabolism. The present ‘perspective’ suggests a more comprehensive and complex role, made possible by lack of glycogen degradation, unless specifically induced by either i) activation of astrocytic receptors, perhaps especially beta-adrenergic, or ii) even small increases in extracellular K+ concentration above its normal resting level. It discusses i) the known importance of glycogenolysis for glutamate formation, requiring pyruvate carboxylation; ii) the established role of K+-stimulated glycogenolysis for K+ uptake in cultured astrocytes, which probably indicates that astrocytes are an integral part of cellular K+ homeostasis in the brain in vivo; and iii) the plausible role of transmitter-induced glycogenolysis, stimulating Na+,K+-ATPase/NKCC1 activity and thereby contributing both to the post-excitatory undershoot in extracellular K+ concentration and the memory-enhancing effect of transmitter-mediated reduction of slow neuronal afterhyperpolarization (sAHP).